Cargando…

No difference in frontal cortical activity during an executive functioning task after acute doses of aripiprazole and haloperidol

Background: Aripiprazole is an atypical antipsychotic drug that is characterized by partial dopamine D2 receptor agonism. Its pharmacodynamic profile is proposed to be beneficial in the treatment of cognitive impairment, which is prevalent in psychotic disorders. This study compared brain activation...

Descripción completa

Detalles Bibliográficos
Autores principales: Bolstad, Ingeborg, Andreassen, Ole A., Groote, Inge R., Haatveit, Beathe, Server, Andres, Jensen, Jimmy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4443021/
https://www.ncbi.nlm.nih.gov/pubmed/26074803
http://dx.doi.org/10.3389/fnhum.2015.00296
_version_ 1782372965091901440
author Bolstad, Ingeborg
Andreassen, Ole A.
Groote, Inge R.
Haatveit, Beathe
Server, Andres
Jensen, Jimmy
author_facet Bolstad, Ingeborg
Andreassen, Ole A.
Groote, Inge R.
Haatveit, Beathe
Server, Andres
Jensen, Jimmy
author_sort Bolstad, Ingeborg
collection PubMed
description Background: Aripiprazole is an atypical antipsychotic drug that is characterized by partial dopamine D2 receptor agonism. Its pharmacodynamic profile is proposed to be beneficial in the treatment of cognitive impairment, which is prevalent in psychotic disorders. This study compared brain activation characteristics produced by aripiprazole with that of haloperidol, a typical D2 receptor antagonist, during a task targeting executive functioning. Methods: Healthy participants received an acute oral dose of haloperidol, aripiprazole or placebo before performing an executive functioning task while blood-oxygen-level-dependent (BOLD) functional magnetic resonance imaging (fMRI) was carried out. Results: There was a tendency towards reduced performance in the aripiprazole group compared to the two other groups. The image analysis yielded a strong task-related BOLD-fMRI response within each group. An uncorrected between-group analysis showed that aripiprazole challenge resulted in stronger activation in the frontal and temporal gyri and the putamen compared with haloperidol challenge, but after correcting for multiple testing there was no significant group difference. Conclusion: No significant group differences between aripiprazole and haloperidol in frontal cortical activation were obtained when corrected for multiple comparisons. This study is registered in ClinicalTrials.gov (identifier: 2009-016222-14).
format Online
Article
Text
id pubmed-4443021
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-44430212015-06-12 No difference in frontal cortical activity during an executive functioning task after acute doses of aripiprazole and haloperidol Bolstad, Ingeborg Andreassen, Ole A. Groote, Inge R. Haatveit, Beathe Server, Andres Jensen, Jimmy Front Hum Neurosci Neuroscience Background: Aripiprazole is an atypical antipsychotic drug that is characterized by partial dopamine D2 receptor agonism. Its pharmacodynamic profile is proposed to be beneficial in the treatment of cognitive impairment, which is prevalent in psychotic disorders. This study compared brain activation characteristics produced by aripiprazole with that of haloperidol, a typical D2 receptor antagonist, during a task targeting executive functioning. Methods: Healthy participants received an acute oral dose of haloperidol, aripiprazole or placebo before performing an executive functioning task while blood-oxygen-level-dependent (BOLD) functional magnetic resonance imaging (fMRI) was carried out. Results: There was a tendency towards reduced performance in the aripiprazole group compared to the two other groups. The image analysis yielded a strong task-related BOLD-fMRI response within each group. An uncorrected between-group analysis showed that aripiprazole challenge resulted in stronger activation in the frontal and temporal gyri and the putamen compared with haloperidol challenge, but after correcting for multiple testing there was no significant group difference. Conclusion: No significant group differences between aripiprazole and haloperidol in frontal cortical activation were obtained when corrected for multiple comparisons. This study is registered in ClinicalTrials.gov (identifier: 2009-016222-14). Frontiers Media S.A. 2015-05-26 /pmc/articles/PMC4443021/ /pubmed/26074803 http://dx.doi.org/10.3389/fnhum.2015.00296 Text en Copyright © 2015 Bolstad, Andreassen, Groote, Haatveit, Server and Jensen. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution and reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neuroscience
Bolstad, Ingeborg
Andreassen, Ole A.
Groote, Inge R.
Haatveit, Beathe
Server, Andres
Jensen, Jimmy
No difference in frontal cortical activity during an executive functioning task after acute doses of aripiprazole and haloperidol
title No difference in frontal cortical activity during an executive functioning task after acute doses of aripiprazole and haloperidol
title_full No difference in frontal cortical activity during an executive functioning task after acute doses of aripiprazole and haloperidol
title_fullStr No difference in frontal cortical activity during an executive functioning task after acute doses of aripiprazole and haloperidol
title_full_unstemmed No difference in frontal cortical activity during an executive functioning task after acute doses of aripiprazole and haloperidol
title_short No difference in frontal cortical activity during an executive functioning task after acute doses of aripiprazole and haloperidol
title_sort no difference in frontal cortical activity during an executive functioning task after acute doses of aripiprazole and haloperidol
topic Neuroscience
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4443021/
https://www.ncbi.nlm.nih.gov/pubmed/26074803
http://dx.doi.org/10.3389/fnhum.2015.00296
work_keys_str_mv AT bolstadingeborg nodifferenceinfrontalcorticalactivityduringanexecutivefunctioningtaskafteracutedosesofaripiprazoleandhaloperidol
AT andreassenolea nodifferenceinfrontalcorticalactivityduringanexecutivefunctioningtaskafteracutedosesofaripiprazoleandhaloperidol
AT grooteinger nodifferenceinfrontalcorticalactivityduringanexecutivefunctioningtaskafteracutedosesofaripiprazoleandhaloperidol
AT haatveitbeathe nodifferenceinfrontalcorticalactivityduringanexecutivefunctioningtaskafteracutedosesofaripiprazoleandhaloperidol
AT serverandres nodifferenceinfrontalcorticalactivityduringanexecutivefunctioningtaskafteracutedosesofaripiprazoleandhaloperidol
AT jensenjimmy nodifferenceinfrontalcorticalactivityduringanexecutivefunctioningtaskafteracutedosesofaripiprazoleandhaloperidol